力行求是，勇于创新
R&D system
BrightGene has built an international R&D system with strong strength, strengthened the industry university research alliance and international exchange and cooperation with a global perspective, and effectively realized the interaction and integration of information, talents, technology and other R&D resources.
The overall area of the R&D facilities of BrightGene has exceeded 6000 ㎡. It has introduced advanced NMR, ICP-MS, 400M NMR and other equipment, and established an analysis center with strong team strength; At the same time, advanced preparation equipment was introduced for the pilot production of preparation products.
After years of continuous R&D and exploration,BrightGene has made breakthroughs in the fields of tumor targeted therapy and immunotherapy, as well as the treatment of fatty liver and diabetes. Many original new drugs have entered or are about to enter clinical research; At the same time, we have successfully developed high-end generic drugs such as aribrin, trobettidine and fondaparinux, and established a highly competitive product line in the fields of anti-tumor, super antibiotics and intravenous iron supplementation.
BrightGene has won a series of honors in the process of rapid development, and has been awarded as "National High tech Enterprise", "Jiangsu Enterprise Technology Center", "Jiangsu Multi chiral Pharmaceutical Engineering Technology Research Center", "Jiangsu Science and Technology Innovation Enterprise", etc. In the future, BrightGene will continue to focus on the research and development of original new drugs and high-end generic drugs, and will adhere to the concept of continuous innovation in the high-speed development, and strive to become a domestic technology leader in the same industry and an innovative enterprise with international competitiveness.
R&D style
R&D technology platform
0512-62620988
Free service hotline
